Comparative Pharmacology
Head-to-head clinical analysis: PHENAPHEN W CODEINE NO 2 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENAPHEN W CODEINE NO 2 versus QOLIANA.
PHENAPHEN W/ CODEINE NO. 2 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is an opioid agonist with affinity for mu-opioid receptors, producing analgesia, cough suppression, and sedation. Acetaminophen is a centrally acting analgesic and antipyretic with unclear mechanism, possibly involving COX-2 inhibition and cannabinoid receptor activation.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
1-2 tablets (codeine 15-30 mg, acetaminophen 325-650 mg) every 4 hours as needed for pain; maximum: 12 tablets per day.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Phenacetin: terminal half-life ~0.5-2 hours (rapidly eliminated; active metabolite APAP has half-life ~2-3 hours). Codeine: terminal half-life ~2.5-4 hours (increased in CYP2D6 poor metabolizers). Acetaminophen: terminal half-life ~1.5-3 hours (prolonged in hepatic impairment or overdose). Clinical context: half-lives are shortened with chronic use due to autoinduction (phenacetin) and unchanged with therapeutic doses.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Phenacetin (active metabolite): renal elimination of conjugated metabolites, primarily as sulfate and glucuronide conjugates; ~60% renal. Codeine: ~90% renal, with 5-15% as free codeine, 10% as norcodeine, and 40-70% as conjugated morphine and norcodeine; ~10% fecal. Apap (acetaminophen): renal elimination of conjugated metabolites, with ~85% excreted in urine as sulfate and glucuronide conjugates, ~5% as unchanged drug, and <5% as cysteine/mercapturate conjugates.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist